An overview of esophageal squamous cell carcinoma proteomics

Journal of Proteomics

Volumn 75, Issue 11, 2012, Pages 3129-3137

  Qi, Yi Jun ^a   Chao, Wei Xia ^a   Chiu, Jen Fu ^b,c  

^a HENAN UNIVERSITY   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Esophageal squamous cell carcinoma; Isobaric tags for relative and absolute quantification (iTRAQ); Mass spectrometry (MS); Proteomics; Stable isotope labeling by amino acids in cell culture (SILAC); Two dimensional electrophoresis (2DE)

Indexed keywords

ALPHA TROPOMYOSIN; CALRETICULIN; CORTACTIN; CYTOKERATIN 13; CYTOKERATIN 6; DESMIN; GALECTIN 7; HEAT SHOCK PROTEIN 90; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PHOSPHOGLYCERATE KINASE; PROFILIN; PROHIBITIN; PYRUVATE KINASE; TUBULIN; ZINC FINGER PROTEIN;

CANCER GROWTH; CARCINOGENESIS; DNA FINGERPRINTING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 84861668900     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.04.025     Document Type: Review

References (59)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Holmes R.S., Vaughan T.L. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007, 17:2-9.
3. Daly J.M., Fry W.A., Little A.G., Winchester D.P., McKee R.F., Stewart A.K., et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000, 190:562-572. [discussion 72-3].
4. Li L.W., Li Y.Y., Li X.Y., Zhang C.P., Zhou Y., Lu S.H. A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma. BMC Cancer 2011, 11:52.
5. Cheng K.K., Day N.E. Nutrition and esophageal cancer. Cancer Causes Control 1996, 7:33-40.
6. Devesa S.S., Blot W.J., Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049-2053.
7. Fan Y.J., Song X., Li J.L., Li X.M., Liu B., Wang R., et al. Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period. World J Surg 2008, 32:1980-1988.
8. Hongo M., Nagasaki Y., Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009, 24:729-735.
9. Chang-Claude J., Becher H., Blettner M., Qiu S., Yang G., Wahrendorf J. Familial aggregation of oesophageal cancer in a high incidence area in China. Int J Epidemiol 1997, 26:1159-1165.
10. Triboulet J.P., Mariette C., Chevalier D., Amrouni H. Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg 2001, 136:1164-1170.
11. Hagymasi K., Tulassay Z. Genetic background of esophageal squamous cell carcinoma. Orv Hetil 2007, 148:1795-1800.
12. Lightdale C.J. Esophageal cancer. American College of Gastroenterology. Am J Gastroenterol 1999, 94:20-29.
13. Wang G.Q. 30-year experiences on early detection and treatment of esophageal cancer in high risk areas. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2001, 23:69-72.
14. Law S., Wong J. The current management of esophageal cancer. Adv Surg 2007, 41:93-119.
15. Iizuka T., Isono K., Kakegawa T., Watanabe H. Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases. Chest 1989, 96:1005-1011.
16. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
17. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
18. Kolch W., Mischak H., Chalmers M.J., Pitt A., Marshall A.G. Clinical proteomics: a question of technology. Rapid Commun Mass Spectrom 2004, 18:2365-2366.
19. Kolch W., Mischak H., Pitt A.R. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond) 2005, 108:369-383.
20. Qi Y., Chiu J.F., Wang L., Kwong D.L., He Q.Y. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 2005, 5:2960-2971.
21. Qi Y.J., He Q.Y., Ma Y.F., Du Y.W., Liu G.C., Li Y.J., et al. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem 2008, 104:1625-1635.
22. Qi Y.J., Wang L.D., Jiao X.Y., Feng X.S., Fan Z.M., Gao S.S., et al. Dysregulation of Annexin II expression in esophageal squamous cell cancer and adjacent tissues from a high-incidence area for esophageal cancer in Henan province. Ai Zheng 2007, 26:730-736.
23. Qi Y.J., Ma Y.F., Du Y.W., Liu G.C., Zhang L.L., Zhang G.M., et al. Character ization and correlation of 14-3-3σ and P53 protein expressions in multi-stage carcinogenesis of esophageal squamous cell carcinoma. J Fourth Mil Med Univ 2007, 28:1834-1837.
24. Ren H.Z., Pan G.Q., Wang J.S., Wen J.F., Wang K.S., Luo G.Q., et al. Reduced stratifin expression can serve as an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Dig Dis Sci 2010, 55:2552-2560.
25. Zhou G., Li H., Gong Y., Zhao Y., Cheng J., Lee P., et al. Proteomic analysis of global alteration of protein expression in squamous cell carcinoma of the esophagus. Proteomics 2005, 5:3814-3821.
26. Chen H.B., Pan K., Tang M.K., Chui Y.L., Chen L., Su Z.J., et al. Comparative proteomic analysis reveals differentially expressed proteins regulated by a potential tumor promoter, BRE, in human esophageal carcinoma cells. Biochem Cell Biol 2008, 86:302-311.
27. Fu L., Qin Y.R., Xie D., Chow H.Y., Ngai S.M., Kwong D.L., et al. Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. Cancer 2007, 110:2672-2681.
28. Zhang J., Wang K., Zhang J., Liu S.S., Dai L., Zhang J.Y. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 2011, 10:2863-2872.
29. Liu Z., Feng J.G., Tuersun A., Liu T., Liu H., Liu Q., et al. Proteomic identification of differentially-expressed proteins in esophageal cancer in three ethnic groups in Xinjiang. Mol Biol Rep 2011, 38:3261-3269.
30. Du X.L., Hu H., Lin D.C., Xia S.H., Shen X.M., Zhang Y., et al. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J Mol Med 2007, 85:863-875.
31. Zhu X., Ding M., Yu M.L., Feng M.X., Tan L.J., Zhao F.K. Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer 2010, 10:290.
32. Nishimori T., Tomonaga T., Matsushita K., Oh-Ishi M., Kodera Y., Maeda T., et al. Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics 2006, 6:1011-1018.
33. Hatakeyama H., Kondo T., Fujii K., Nakanishi Y., Kato H., Fukuda S., et al. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics 2006, 6:6300-6316.
34. Jazii F.R., Najafi Z., Malekzadeh R., Conrads T.P., Ziaee A.A., Abnet C., et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006, 12:7104-7112.
35. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000, 60:1777-1788.
36. Disis M.L., Pupa S.M., Gralow J.R., Dittadi R., Menard S., Cheever M.A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15:3363-3367.
37. Chen G., Wang X., Yu J., Varambally S., Yu J., Thomas D.G., et al. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 2007, 67:3461-3467.
38. Hong S.H., Misek D.E., Wang H., Puravs E., Giordano T.J., Greenson J.K., et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004, 64:5504-5510.
39. Bergqvist A.S., Bergqvist M., Brattstrom D., Hesselius P., Larsson A., Brodin O., et al. Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res 2001, 21:4141-4145.
40. Veale R.B., Thornley A.L., Scott E., Antoni A., Segal I. Quantitation of autoantibodies to cytokeratins in sera from patients with squamous cell carcinoma of the oesophagus. Br J Cancer 1988, 58:767-772.
41. Shimada H., Kuboshima M., Shiratori T., Nabeya Y., Takeuchi A., Takagi H., et al. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 2007, 30:97-103.
42. Shimada H., Nakashima K., Ochiai T., Nabeya Y., Takiguchi M., Nomura F., et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol 2005, 26:77-86.
43. Fujita Y., Nakanishi T., Hiramatsu M., Mabuchi H., Miyamoto Y., Miyamoto A., et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006, 12:6415-6420.
44. Fujita Y., Nakanishi T., Miyamoto Y., Hiramatsu M., Mabuchi H., Miyamoto A., et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 2008, 263:280-290.
45. Liu W.L., Zhang G., Wang J.Y., Cao J.Y., Guo X.Z., Xu L.H., et al. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2008, 375:440-445.
46. Brichory F.M., Misek D.E., Yim A.M., Krause M.C., Giordano T.J., Beer D.G., et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001, 98:9824-9829.
47. Dong J., Zeng B.H., Xu L.H., Wang J.Y., Li M.Z., Zeng M.S., et al. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med 2010, 8:81.
48. Wen J., Zheng B., Hu Y., Zhang X., Yang H., Li Y., et al. Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. Int J Oncol 2010, 36:265-274.
49. Langer R., Ott K., Specht K., Becker K., Lordick F., Burian M., et al. Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. Clin Cancer Res 2008, 14:8279-8287.
50. Ong S.E., Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005, 1:252-262.
51. Ong S.E., Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc 2006, 1:2650-2660.
52. Kashyap M.K., Harsha H.C., Renuse S., Pawar H., Sahasrabuddhe N.A., Kim M.S., et al. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther 2010, 10:796-810.
53. Pawar H., Kashyap M.K., Sahasrabuddhe N.A., Renuse S., Harsha H.C., Kumar P., et al. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther 2011, 12:510-522.
54. Wang L.D., Wang D.C., Zheng S., Fan Z.M., Li J.L., Feng C.W., et al. Serum proteomic profiles of the subjects with esophageal precancerous and cancerous lesions from Linzhou, an area with high incidence of esophageal cancer in Henan Province, Northern China. Ai Zheng 2006, 25:549-554.
55. Wang Y., Zhang Z.S., Liu F., Mao Y.S., Zhang J.S., Zhang D.C., et al. A serum pattern for the diagnosis of esophageal squamous cell carcinoma. Chin J Lab Med 2004, 27:634-637.
56. Liu C.Z., Zhu P.Y., Shi M.X., Liu J.B., Liao P., Xiang C.Q., et al. Serum proteomic spectra of esophageal squamous cell carcinoma patients analyzed with IMAC3 protein chip. Ai Zheng 2008, 27:272-278.
57. Xu S.Y., Liu Z., Ma W.J., Sheyhidin I., Zheng S.T., Lu X.M. New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma. Biomarkers 2009, 14:340-346.
58. Hayashida Y., Honda K., Osaka Y., Hara T., Umaki T., Tsuchida A., et al. Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res 2005, 11:8042-8047.
59. Maher S.G., McDowell D.T., Collins B.C., Muldoon C., Gallagher W.M., Reynolds J.V. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann Surg 2011, 254:809-816. [discussion 16-7].